MRGPRX2 Modulator Compounds for Diverse Ligand Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders mediated by MRGPRX2, such as pseudo-allergic reactions, chronic itch, inflammation, and pain, are inadequate due to limited understanding of these receptors and their activation by diverse ligands.
Innovation Solution
Development of modulators, including inverse agonists and competitive antagonists, represented by specific compounds of Formula (I) and their derivatives, to target and regulate MRGPRX2 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for MRGPRX2-mediated disorders, then existing therapeutic options are available, but treatment effectiveness is inadequate due to limited understanding of receptor activation mechanisms
Solution Approach 1:
The patent introduces modulator compounds as intermediary substances that mediate between the researcher and the MRGPRX2 receptor system. These compounds serve as tools to probe and understand receptor activation mechanisms while simultaneously providing therapeutic effects. The modulators act as intermediaries that translate the complex biological interactions into measurable and controllable therapeutic outcomes.
2Adaptability or versatility
If diverse ligands activate MRGPRX2, then the receptor mediates multiple disorders including pseudo-allergic reactions, chronic itch, inflammation, and pain, but developing targeted treatments becomes more complex
Solution Approach 1:
The patent develops modulator compounds with universal applicability across multiple MRGPRX2-mediated disorders. A single modulator compound can address pseudo-allergic reactions, chronic itch, inflammation, and pain by targeting the common MRGPRX2 receptor pathway. This multi-functional approach simplifies treatment development compared to creating separate therapies for each condition.
Solution Approach 2:
The patent employs parameter changes in the modulator compound design, specifically adjusting the pKa value to optimize receptor interaction. By modifying chemical parameters such as pKa, the modulators can effectively bind to and modulate MRGPRX2 across different physiological conditions and disease states, providing a unified therapeutic strategy for diverse ligand-induced disorders.
3Adaptability or versatility
If modulators are designed to block multiple chemical entities, then therapeutic benefits are enhanced for multiple conditions, but the molecular structure complexity increases
Solution Approach 1:
The patent utilizes parameter changes, particularly pKa optimization, to achieve multi-ligand blocking capability without proportionally increasing molecular complexity. By adjusting the pKa parameter of the modulator compounds, they can effectively interact with diverse ligands and the MRGPRX2 receptor through electrostatic and hydrophobic interactions, achieving broad-spectrum blocking with relatively streamlined molecular structures.
Data Source
AI summary
The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof,which are useful as modulators of the G-coupled protein receptor MRGPRX2, as well as methods for using such compounds to treat or ameliorate certain diseases or conditions. In some embodiments, the invention provides methods for using such compounds to treat atopic dermatitis, inflammatory disorders, autoimmune disorders, itch-associated conditions, pseudo-allergic reactions, pain-associated conditions and cancer-associated conditions.